Geneva, Switzerland, July 19, 2018.
Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.
During the past 10+ years Institut Clayton de la Recherche has funded research at the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva, mostly in the understanding of the biochemistry of cell adhesion molecules and extracellular matrix-related proteins in leukocyte transmigration and tumor angiogenesis.As a result of this work monoclonal antibodies blocking JAM-C and Olfml3 have been obtained.
They have shown initial promise in the treatment of a wide set of cancer indications.
We are delighted to have the opportunity to continue the development of the programs that have been initiated at the University of Geneva. Antibodies blocking JAM-C and Olfml3 have so far shown impressive potential in animal models of several cancer indications
said Ignacio Faus, co-founder and Chairman of the Board of Abologix.